With the Veterans Health Administration (VHA), Biogen is working to finalize a multi-year agreement in order to support access for veterans throughout the VHA system. veterans also faces increased risk for the disease as a result of their service, including conditions such as post-traumatic stress disorder, traumatic brain injury, and other factors.
![hero lab online beta access hero lab online beta access](https://img.etimg.com/thumb/msid-86191132,width-1070,height-580,imgsize-56968,overlay-ettech/photo.jpg)
The ethnically diverse population of U.S. Black/African Americans and Latinx people are disproportionally more likely to develop Alzheimer’s disease as well as more likely to have missed diagnoses compared to non-Hispanic white Americans. Multiple Collaborations to Address Health Equityīiogen and Eisai are committed to addressing health equity for underserved and underrepresented populations that are at higher risk for Alzheimer’s disease. Biogen Support Service Coordinators can be reached at 1-83.īiogen and Eisai have also established a program with Labcorp and Mayo Clinic Laboratories to help physicians and patients access cerebrospinal fluid (CSF) diagnostic laboratory testing to aid in the diagnosis of Alzheimer’s disease. The service coordinators can answer questions about Alzheimer’s disease and ADUHELM treatment, assess financial assistance options for eligible patients, and locate healthcare providers and infusion sites, among other topics. Personal Biogen Support Service Coordinators are now available to patients and their families to provide one-on-one support.
![hero lab online beta access hero lab online beta access](https://www.freecodecamp.org/news/content/images/2022/01/collection-ivy-league-moocs-social-2.jpg)
![hero lab online beta access hero lab online beta access](https://i.ytimg.com/vi/ualUfSfTFHk/maxresdefault.jpg)
“It is critically important for Eisai and Biogen to not only establish these access programs but to champion their reach, especially in underserved patient communities.” and President, Neurology Business Group, Eisai Co., Ltd. in nearly 20 years, bringing long-awaited hope for patients and families living with this neurodegenerative disease,” said Ivan Cheung, Chairman of Eisai Inc. “ADUHELM is the first new treatment for Alzheimer’s disease to be approved in the U.S. “We are committed to access and health equity as top priorities and will continue working with multiple stakeholders with the goal of helping patients who may benefit from treatment obtain care as quickly as possible.” “We feel a great sense of purpose and responsibility to turn the hope of today’s FDA approval of ADUHELM into a reality for people living with Alzheimer’s disease and their families,” said Alisha Alaimo, President of Biogen U.S. These initiatives aim to help patients and their families understand the disease, navigate the diagnostic journey, secure culturally competent care and afford treatment.
![hero lab online beta access hero lab online beta access](https://www.lonewolfdevel.com/Styles/Images/HLOnlineSlider.jpg)
subsidiary of Eisai Co., Ltd., announced a range of programs intended to support access for all qualified patients, including traditionally underserved populations. Food and Drug Administration’s (FDA) accelerated approval of ADUHELM TM (aducanumab-avwa) as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease by reducing amyloid beta plaques in the brain, Biogen (Nasdaq: BIIB) and Eisai Inc., U.S. and WOODCLIFF LAKE, N.J., J(GLOBE NEWSWIRE) - Following today’s U.S. Value-based agreements in progress with Cigna and other payersĬAMBRIDGE, Mass. Programs now available to support patients and families with their treatment journeyĬollaborations with Veterans Health Administration, CVS Health and NAFC focused on health disparities in underserved communities